Uniwersytecki Dzieciecy Szpital Kliniczny im. L. Zamenhofa

Bialystok 15-274

1 studies enrolling now · 4 studies all time

What they study most

Autosomal Recessive Polycystic Kidney (ARPKD), Children, Chronic Kidney Disease, Neurogenic Detrusor Overactivity, Proteinuria

Studies at this site

• A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD) — Recruiting now
• A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria — Recruiting now
• A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria — Recruiting now
• Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC — Recruiting now